ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2307

Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF

Hilde Hammer1, Tore Kvien 2 and Lene Terslev 3, 1Diakonhjemmet Hospital, Oslo, Norway, 2Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid arthritis (RA), ultrasound and anti-CCP antibodies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Ultrasound is sensitive for detection of inflammatory changes in patients with rheumatoid arthritis (RA). Intermetatarsal bursitis (IMB) may be detected by use of longitudinal dorsal scans between the metatarsophalangeal joints. The present objective was to explore the prevalence of IMB and its associations with subjective, clinical and laboratory assessments in established RA patients.

Methods: A total of 209 patients with RA (mean (SD) age 53 (13) years, disease duration 10 (9) years, 81% women, 79% anti-CCP positive) were included when initiating biological disease modifying antirheumatic drugs (bDMARD). The patients were assessed at baseline and after 1, 2, 3, 6 and 12 months with patient’s global disease activity VAS, clinical examination (assessor’s disease activity VAS, tender and swollen joint counts performed by a study nurse) and laboratory variables (ESR, CRP, anti-CCP and rheumatoid factor (RF)). Composite clinical scores (DAS28(ESR), CDAI and SDAI) were calculated. The presence of patient reported joint pain (PRJP) was assessed at joint level by use of a manikin (bilateral wrist, MCP1-5, PIP2-3, elbow, knee, ankle, MTP1-5). Each joint was scored 0-3 reflecting the level of spontaneous joint pain the last day. All ultrasound examinations (semi-quantitative scoring (0-3)) of grey scale synovitis (GS) and power Doppler (PD) (PIP 2-3, MCP 1-5, wrist, elbow, knee, talocrural, MTP 1-5 and extensor carpi ulnaris (ECU)/tibialis posterior (TP) tendons bilaterally) were performed by one rheumatologist (HBH) with high intra-reader reliability (Siemens Acuson Antares, excellence version, 5-13 MHz probe). In addition, both feet were at each examination assessed by dorsal longitudinal scan of all spaces between the MTP joints for IMB. Baseline GS and PD ultrasound and PRJP sum scores of MTP 1-5 bilaterally were calculated. Associations were explored by use of Mann-Whitney test and Odds Ratios (OR).

Results: A total of 43 patients (20.6%) had uni- or bilaterally IMB (27.8% right side, 41.9% left side and 23.3% bilaterally, while 7.0%.had no description of side). The patients had up to 4 IMB (n=1 in 72.1%, n=2 in 14.0%, n=3 in 7.0% or n=4 in 7.0%. The figure shows a typical GS and PD ultrasound of an IMB. The locations of IMB (n=64) were: 4.7% between MTP1 and 2, 32.8% between MTP 2 and 3, 57.8% between MTP 3 and 4, 4.7% between MTP 4 and 5. The presence of IMB was not associated with sum score of baseline GS, PD or PRJP, and not with any of the clinical assessments. However, patients with versus without IMB had significantly higher MTP scores of GS and PD (p=0.05 and p=0.002, respectively), but no difference in PRJP. In addition, presence of IMB was associated with anti-CCP (OR (95% CI) 4.1 (1.2-14.0) and RF (3.7 (1.4-10.1), where 93% of patients with IMB were anti-CCP positive and 87% RF positive.

Conclusion: Intermetatarsal bursitis is quite common in established RA patients and was primarily found between MTP 2-3 and 3-4. It was associated with higher levels of ultrasound MTP joint inflammation and presence of anti-CCP and RF. Thus, ultrasound examination of forefeet should include exploring for this pathology which may indicate more severe disease.


UL av IMB for abstrakt


Disclosure: H. Hammer, None; T. Kvien, AbbVie, 2, 8, Biogen, 5, 8, Biogen, Egis, Eli Lilly, Hikma, Mylan, Novartis/Sandoz, Oktal, Hospira/Pfizer, Sanofi and UCB, 5, BMS, 8, Celltrion, 8, Egis, 5, 8, Eli Lilly, 5, 8, Hikma, 5, 8, Hospira/Pfizer, 2, 5, 8, MSD, 2, 8, Mylan, 5, 8, Novartis, 8, Novartis/Sandoz, 5, 8, Oktal, 5, 8, Orion Pharma, 8, Roche, 2, 8, Sandoz, 8, Sanofi, 5, 8, UCB, 5, 8; L. Terslev, None.

To cite this abstract in AMA style:

Hammer H, Kvien T, Terslev L. Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/intermetatarsal-bursitis-is-prevalent-in-patients-with-established-rheumatoid-arthritis-and-is-associated-with-anti-ccp-and-rf/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intermetatarsal-bursitis-is-prevalent-in-patients-with-established-rheumatoid-arthritis-and-is-associated-with-anti-ccp-and-rf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology